Understanding the two faces of the COVID-19 immune response to predict clinical course and define strategies for early and late phase intervention

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.043E+13

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principle Investigator

  • Research Location

    Netherlands, Europe
  • Lead Research Institution

    University Medical Center Utrecht
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



Project description The immune system plays a striking double role in COVID-19. An effective immune response ensures that the virus is attacked and cleared away, but if that does not work properly, a hyper-activation of the immune system appears to arise, which can lead to serious problems. It is unclear what exactly goes wrong in the immune system in patients with a severe course and how they can best be treated. The use of immunosuppressive medications is one of the possible strategies. Research and expected outcomes In this study, a collaboration of the UMCU, RIVM and VUmc, a model of the underlying immune response in different phases of COVID is developed by measuring functional cellular defense and circulating protein profiles of patients of different ages and with a variation in disease severity. -19. In addition, predictive biomarkers will be identified and validated that provide insight into optimal timing for specific treatments.